Free Trial

Avidity Biosciences (RNA) News Today

→ Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad)
Free RNA Stock Alerts
$26.60
+0.56 (+2.15%)
(As of 06/7/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends
June 8 at 1:30 AM | americanbankingnews.com
Avidity Biosciences (NASDAQ:RNA) Trading Down 5.7% on Insider Selling
June 7 at 3:25 PM | marketbeat.com
Avidity Biosciences (NASDAQ:RNA) Trading 3.2% Higher
Avidity Biosciences (NASDAQ:RNA) Stock Price Up 3.2%
June 7 at 5:14 AM | marketbeat.com
Steward Partners Investment Advisory LLC Has $534,000 Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)
Steward Partners Investment Advisory LLC lifted its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 202.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 59,000 shares of the biotechnology compa
June 7 at 4:52 AM | insidertrades.com
Sarah Boyce Sells 28,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock
June 6 at 1:32 PM | marketbeat.com
Avidity Biosciences (NASDAQ:RNA) Trading Down 5.7% After Insider Selling
Avidity Biosciences (NASDAQ:RNA) Shares Down 5.7% After Insider Selling
June 6 at 7:20 AM | insidertrades.com
Avidity Biosciences, Inc. (NASDAQ:RNA) CEO Sarah Boyce Sells 28,000 Shares
June 4, 2024 | marketbeat.com
Charles Schwab Investment Management Inc. Acquires 30,674 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)
Charles Schwab Investment Management Inc. boosted its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 6.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 545,771 shares of the biotechnolog
June 1, 2024 | marketbeat.com
Trexquant Investment LP Sells 90,719 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)
Trexquant Investment LP trimmed its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 56.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,874 shares of the biotechno
May 30, 2024 | marketbeat.com
Artisan Partners Limited Partnership Lowers Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)
Artisan Partners Limited Partnership decreased its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 2.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,103,022 shares of the biotechnology company's s
May 29, 2024 | finance.yahoo.com
Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress
May 29, 2024 | fool.com
2 Potentially High-Reward Growth Stocks to Buy Right Now
May 28, 2024 | marketbeat.com
Avidity Biosciences (NASDAQ:RNA) Stock Price Down 4.3%
Avidity Biosciences (NASDAQ:RNA) Stock Price Down 4.3%
May 25, 2024 | marketbeat.com
Dynamic Technology Lab Private Ltd Raises Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)
Dynamic Technology Lab Private Ltd increased its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 114.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,788 shares of the
May 23, 2024 | investorplace.com
Dip Then Rip? 3 Nasdaq Stocks to Buy Before the Rebound
May 22, 2024 | insidertrades.com
Arthur A. Levin Sells 5,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock
May 22, 2024 | marketbeat.com
Avidity Biosciences, Inc. (NASDAQ:RNA) Given Average Recommendation of "Buy" by Brokerages
Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) has been given an average recommendation of "Buy" by the six research firms that are currently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price target
May 21, 2024 | markets.businessinsider.com
Avidity Biosciences Poised for Growth: Buy Rating Affirmed Amidst Encouraging Competitive Landscape
May 21, 2024 | prnewswire.com
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 21, 2024 | marketbeat.com
Jump Financial LLC Sells 40,093 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)
Jump Financial LLC cut its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 36.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 70,594 shares of the biotechnology company's stock after selling 4
May 20, 2024 | marketbeat.com
Avidity Biosciences (NASDAQ:RNA) Hits New 52-Week High at $30.55
Avidity Biosciences (NASDAQ:RNA) Hits New 12-Month High at $30.55
May 19, 2024 | investing.com
Avidity Biosciences Inc (RNA)
May 19, 2024 | seekingalpha.com
Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline
May 19, 2024 | finance.yahoo.com
Bank of America Predicts up to ~200% Surge for These 2 ‘Strong Buy’ Stocks
May 17, 2024 | insidertrades.com
Avidity Biosciences, Inc. (NASDAQ:RNA) CFO Sells $2,121,000.00 in Stock
May 15, 2024 | marketbeat.com
Avidity Biosciences (NASDAQ:RNA) Issues Quarterly Earnings Results
Avidity Biosciences (NASDAQ:RNA - Get Free Report) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.02. The business had revenue of $3.54 million for the quarter, compared to analyst estimates of $7.09 million. Avidity Biosciences had a negative return on equity of 37.98% and a negative net margin of 2,103.78%.
May 15, 2024 | prnewswire.com
Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors
May 14, 2024 | marketbeat.com
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week High at $28.19
Avidity Biosciences (NASDAQ:RNA) Hits New 12-Month High at $28.19
May 13, 2024 | markets.businessinsider.com
Avidity Biosciences: Strong Buy on Promising Trials and Solid Financials
May 10, 2024 | marketbeat.com
Avidity Biosciences (NASDAQ:RNA) Stock Rating Reaffirmed by Chardan Capital
Chardan Capital reiterated a "buy" rating and issued a $33.00 price target on shares of Avidity Biosciences in a research note on Friday.
May 10, 2024 | finanznachrichten.de
Avidity Biosciences, Inc.: Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
May 10, 2024 | investorplace.com
RNA Stock Earnings: Avidity Biosciences Misses EPS, Beats Revenue for Q1 2024
May 9, 2024 | seekingalpha.com
Avidity Biosciences files automatic mixed shelf
May 9, 2024 | markets.businessinsider.com
Buy Rating Justified for Avidity Biosciences Amid Strong Drug Candidate Prospects and Regulatory Advancements
May 9, 2024 | prnewswire.com
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
May 8, 2024 | markets.businessinsider.com
Avidity Receives Breakthrough Therapy Designation For Its Myotonic Dystrophy Type 1 Drug Candidate
May 8, 2024 | msn.com
Avidity gets FDA breakthrough therapy status for DM1 drug
May 8, 2024 | prnewswire.com
Avidity Biosciences to Participate in Upcoming Investor Conference
May 8, 2024 | finance.yahoo.com
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1
May 7, 2024 | marketbeat.com
Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) CEO Sells 28,000 Shares of Stock
Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) CEO Sarah Boyce sold 28,000 shares of the firm's stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $25.54, for a total value of $715,120.00. Following the sale, the chief executive officer now directly owns 112,117 shares in the company, valued at approximately $2,863,468.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
May 4, 2024 | msn.com
B of A Securities Initiates Coverage of Avidity Biosciences (RNA) with Buy Recommendation
May 3, 2024 | markets.businessinsider.com
Navigating 7 Analyst Ratings For Avidity Biosciences
May 3, 2024 | seekingalpha.com
BofA starts Avidity at buy, cites upcoming clinical data
May 3, 2024 | marketbeat.com
Avidity Biosciences (NASDAQ:RNA) Coverage Initiated by Analysts at Bank of America
Bank of America began coverage on shares of Avidity Biosciences in a research note on Friday. They issued a "buy" rating and a $40.00 price objective for the company.
April 30, 2024 | marketbeat.com
129,414 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Purchased by abrdn plc
abrdn plc bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 129,414 shares of the biotechnology company's stock, valued at approximately $1,171,000. abrdn plc
April 27, 2024 | marketbeat.com
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Rating of "Buy" from Brokerages
Shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) have been assigned a consensus rating of "Buy" from the six brokerages that are covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year target price
April 22, 2024 | marketbeat.com
Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Director Sells 5,000 Shares of Stock
Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) Director Arthur A. Levin sold 5,000 shares of the stock in a transaction dated Friday, April 19th. The shares were sold at an average price of $22.82, for a total transaction of $114,100.00. Following the completion of the sale, the director now owns 14,830 shares of the company's stock, valued at approximately $338,420.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
April 22, 2024 | marketbeat.com
Avidity Biosciences (NASDAQ:RNA) Stock Price Up 6.5%
Avidity Biosciences (NASDAQ:RNA) Trading 6.5% Higher
April 22, 2024 | marketbeat.com
Mirae Asset Global Investments Co. Ltd. Has $1.50 Million Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)
Mirae Asset Global Investments Co. Ltd. grew its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 301.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 166,019 shares of the biotechnology company's stock afte
April 21, 2024 | marketbeat.com
Raymond James & Associates Increases Position in Avidity Biosciences, Inc. (NASDAQ:RNA)
Raymond James & Associates boosted its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 39.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 129,921 shares of the biotechnology
April 17, 2024 | marketbeat.com
Raymond James Financial Services Advisors Inc. Raises Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)
Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 149.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 86,611 sh
Get Avidity Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter.

Time is Running Out - June 25th Deadline Approaching! (Ad)

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

That will slam shut June 25.

RNA Media Mentions By Week

RNA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RNA
News Sentiment
▼
0.83

0.76
▲
Average
Medical
News Sentiment

RNA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RNA Articles
This Week
▼
8

3
▲
RNA Articles
Average Week

Get Avidity Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:RNA) was last updated on 6/9/2024 by MarketBeat.com Staff

From Our Partners
Collapse of the Petrodollar
The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...
Colonial Metals | Sponsored
Time is Running Out - June 25th Deadline Approaching!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRIL...
Paradigm Press | Sponsored
Breaking - The US Gov. Seized CITGO
Do you want an investment that can double or triple your money in the next three months? The US Court is cu...
Augury Research | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
Urgent alert: open this for a huge profit potential
This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...
Timothy Sykes | Sponsored
Who are Nvidia’s Silent Partners?
Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.
Weiss Ratings | Sponsored